Document is current
Any future updates will be listed below
-
Authors
Domenico, Dylan
Gundem, Gunes https://orcid.org/0000-0002-0070-9859
Levine, Max F. https://orcid.org/0000-0001-5156-9086
Arango-Ossa, Juan Esteban https://orcid.org/0000-0003-1109-6178
Robbe, Pauline
Asimomitis, Georgios https://orcid.org/0000-0002-9479-5451
Cobbs, Cassidy https://orcid.org/0000-0003-4465-8894
Stockfisch, Emily
O’Donohue, Tara
Brierley, Charlotte
Senz, Janine
Cochrane, Dawn
Mohibullah, Neeman
Bhanot, Umesh https://orcid.org/0000-0001-6656-1239
Silber, Joachim
Shukla, Neerav
Shah, Sohrab P. https://orcid.org/0000-0001-6402-523X
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Zivanovic, Oliver
McPherson, Andrew https://orcid.org/0000-0002-5654-5101
Schuh, Anna https://orcid.org/0000-0002-3938-8490
Kung, Andrew L. https://orcid.org/0000-0002-9091-488X
Papaemmanuil, Elli https://orcid.org/0000-0003-1709-8983
- License Information
-
More Information
Article History
Received: 26 February 2024
Accepted: 16 October 2025
First Online: 27 November 2025
Competing interests
: G.G. is a consultant in Isabl Inc. B. W. reports a research grant from REPARE Therapeutics paid to the institution, and has an immediate family member who is employed by AstraZeneca, outside the submitted work. A.L.K. is on the Scientific Advisory Board of Emendo Biotherapeutics, Karyopharm Therapeutics, Imago BioSciences, and DarwinHealth; is co-Founder and on the Scientific Advisory Board of Isabl; has equity interest in Imago BioSciences, Emendo Biotherapeutics and Isabl; is an inventor of MSK intellectual property licensed to Isabl; and receives royalty income from Labcorp. E.P. is a founder, equity holder and holds fiduciary roles in Isabl Inc. The remaining authors declare no competing interests.
